Relay Therapeutics Inc. (RLAY) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
20D Institutional Volume Accumulation (±11.9% realized swing band)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While RLAY currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($18.52) and Max Pain ($20.44) forces dealer call-delta covering toward $22.33.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Relay Therapeutics Inc. (RLAY) slipped -1.12% to $19.47, trading at 88% of its 52-week range ($5.95 – $21.27). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living
Is TNGX a good stock to buy? We came across a bullish thesis on Tango Therapeutics, Inc. on BioEquity Watch’s Substack. Since the thesis was published on August 28th, TNGX shares have edged lower as investors weighed upd
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +53.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on RLAY today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for RLAY. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Relay Therapeutics Inc. (RLAY) ranks #807 by composite RQD confidence (35/100, grade D-) and #175 by equity capitalization ($4.27B). Within this direct 5-issuer industry benchmark cohort, RLAY leads on earnings valuation at N/A trailing P/E, while ADPT leads on capital efficiency and profitability with -12.5% ROIC and 74.2% gross margin. ADPT currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with RLAY at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RLAY
ACTIVE
Relay Therapeutics Inc. | D- | 35/100 | — | — | -35.0% | -1.12% | $4.27B | Benchmark Subject |
| IOVA Iovance Biotherapeutics Inc. | D | 48/100 | — | 34.3% | -35.0% | -35.45% | $4.33B | /iova-vs-rlay → |
| ADPT Adaptive Biotechnologies Corporation | D | 51/100 | — | 74.2% | -12.5% | -0.70% | $4.50B | /adpt-vs-rlay → |
| TARS Tarsus Pharmaceuticals Inc. | D | 46/100 | — | — | -24.1% | +2.98% | $3.66B | /tars-vs-rlay → |
| CRSP CRISPR Therapeutics AG | D | 44/100 | — | — | -30.6% | +0.28% | $5.25B | /crsp-vs-rlay → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Relay Therapeutics Inc. (RLAY) reported GAAP revenue of $15.4M (+53.4% vs. FY2024 revenue of $10.0M , and -39.9% cumulative change since FY2023) , GAAP net income of -$276.5M, operating cash flow of -$235.5M, and free cash flow of -$235.9M (+6.1% YoY). On the balance sheet, RLAY closed FY2025 with $621.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $15.4M | -$276.5M | -$235.5M | -$235.9M | $621.3M | — |
| FY2024 (FY) | 2024-12-31 | $10.0M | -$337.7M | -$249.1M | -$251.1M | $871.3M | — |
| FY2023 (FY) | 2023-12-31 | $25.5M | -$342.0M | -$300.3M | -$300.3M | — | — |
As of 2026-11-01, Relay Therapeutics Inc. (NASDAQ: RLAY) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $19.47 (-1.12% 1D, market cap $4.27B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RLAY ranks #807 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), RLAY carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IOVA (Iovance Biotherapeutics Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $4.33B) and ADPT (Adaptive Biotechnologies Corporation) posts a D grade (51/100 RQD, P/E N/A, ROIC -12.5%, cap $4.50B). Among the 5-stock peer group, RLAY leads on earnings multiple (N/A) while ADPT leads on capital efficiency (-12.5% ROIC).
Per RLAY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001812364), Relay Therapeutics Inc. generated $15.4M in revenue (+53.4% YoY), -$276.5M in net income, and -$235.9M in free cash flow against $621.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
RLAY last traded at $19.47 (-1.12% on volume of 1,945,397 shares), positioning the stock +5.13% above its 50-day simple moving average ($18.52) and +29.80% above its 200-day simple moving average ($15.00). Across its 52-week range of $5.95 to $21.27, RLAY sits at the 88.3% percentile with a 14-day RSI of 50.0 (NEUTRAL RANGE) and an implied next-earnings move of ±11.9% ($17.15 to $21.79).
Why RLAY Stock slipped -1.12% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.